Evidence map›Paper›PMID 29581542›Full record

ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2018

Detailed genomic characterization identifies high heterogeneity and histotype-specific genomic profiles in adrenocortical carcinomas.

Simona Vatrano, Marco Volante, Eleonora Duregon, Jessica Giorcelli, Stefania Izzo, Ida Rapa, Arianna Votta, Antonina Germano, Giorgio Scagliotti, Alfredo Berruti and 2 more

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Estrogen Receptors-Mediated Apoptosis in Hormone-Dependent Cancers.International journal of molecular sciences · 2022
    Review
  8. Review
  9. Review
  10. SIRT1 is involved in adrenocortical cancer growth and motility.Journal of cellular and molecular medicine · 2021
    Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Simona VatranoDepartment of Oncology, University of Turin at San Luigi Hospital, Orbassano, Turin, Italy.
Marco VolanteDepartment of Oncology, University of Turin at San Luigi Hospital, Orbassano, Turin, Italy. marco.volante@unito.it.
Eleonora DuregonDepartment of Oncology, University of Turin at San Luigi Hospital, Orbassano, Turin, Italy.
Jessica GiorcelliDepartment of Oncology, University of Turin at San Luigi Hospital, Orbassano, Turin, Italy.
Stefania IzzoDepartment of Oncology, University of Turin at San Luigi Hospital, Orbassano, Turin, Italy.
Ida RapaDepartment of Oncology, University of Turin at San Luigi Hospital, Orbassano, Turin, Italy.
Arianna VottaDepartment of Oncology, University of Turin at San Luigi Hospital, Orbassano, Turin, Italy.
Antonina GermanoDepartment of Oncology, University of Turin at San Luigi Hospital, Orbassano, Turin, Italy.
Giorgio ScagliottiDepartment of Oncology, University of Turin at San Luigi Hospital, Orbassano, Turin, Italy.
Alfredo BerrutiOncology Unit, University of Brescia, Brescia, Italy.
Massimo TerzoloInternal Medicine, Department of Clinical and Biological Sciences, University of Turin at San Luigi Hospital, Orbassano, Turin, Italy.
And Mauro PapottiDepartment of Oncology, University of Turin at Molinette Hospital, Turin, Italy.
University of Turin · ITFondazione Ricerca Molinette · ITUniversity of Brescia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Molecular characterization of adrenocortical carcinoma has been recently established, but the correlation between molecular profiles and clinical and pathological characteristics is still poorly defined with no data available about genetic heterogeneity along disease progression. In this scenario, a detailed molecular profile was correlated with clinical and pathological characteristics in adrenocortical carcinoma patients to identify potentially novel biomarkers. Targeted next-generation sequencing and copy number variation analyses for 18 most frequently altered genes in adrenocortical carcinoma were assessed on 62 adult cases (including 10 with matched primary and metastatic/recurrence samples) and results correlated with major clinical and pathological characteristics of tumors. A total of 433 somatic deleterious genetic alterations (328 gene mutations and 105 copy number variations) were identified in 57/62 cases, five resulted wild type for all genes tested. TERT, CDK4, ZNRF3,and RB1 were altered in more than 30% of cases. Among histological variants genotypes were significantly different. Lowest mutation burden was found in the oncocytic type (p = 0.006), whereas the highest with a prevalence of RB1 (p = 0.001) and CDK4 (p = 0.002) was found in the conventional and myxoid ones, respectively. None of the 10 cases with matched samples showed a stable genotype along tumor progression, although allelic frequencies or percentages of altered nuclei at fluorescence in situ hybridization were in most cases similar among different tumor samples for genes that were stable along tumor progression. Among individual genes, an altered p53/Rb1 pathway was the strongest adverse molecular signature, being associated with high Ki-67 index, high tumor stage, aggressive disease status, and shorter disease-free survival. The genomic signature in adrenocortical carcinoma is changing along tumor progression and is associated with specific clinical and pathological features, including histological variant and prognosis.

Indexed as

AdolescentAdrenal Cortex NeoplasmsAdrenocortical CarcinomaAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedMutationYoung Adult

Identifiers

PMID29581542
OpenAlexW2795293970

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.